Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-412-8400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.04 million
Profitability
Miscellaneous
Employees77
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Tocagen (NASDAQ:TOCA) Frequently Asked Questions
What is Tocagen's stock symbol?
Tocagen trades on the NASDAQ under the ticker symbol "TOCA."
How were Tocagen's earnings last quarter?
Tocagen Inc (NASDAQ:TOCA) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.04. The firm earned $0.01 million during the quarter, compared to analyst estimates of $0.50 million. Tocagen had a negative return on equity of 115.81% and a negative net margin of 300.42%. View Tocagen's Earnings History.
When is Tocagen's next earnings date?
What price target have analysts set for TOCA?
9 Wall Street analysts have issued twelve-month target prices for Tocagen's stock. Their forecasts range from $1.00 to $28.00. On average, they expect Tocagen's stock price to reach $11.4150 in the next year. This suggests a possible upside of 1,308.7% from the stock's current price. View Analyst Price Targets for Tocagen.
What is the consensus analysts' recommendation for Tocagen?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.
What are Wall Street analysts saying about Tocagen stock?
Here are some recent quotes from research analysts about Tocagen stock:
- 1. According to Zacks Investment Research, "Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company which focuses on retroviral gene therapy platforms. The company's lead product candidate consists of Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen, Inc. is based in San Diego, United States. " (9/18/2019)
- 2. HC Wainwright analysts commented, "We lower our rating of TOCA to and considering the limited visibility of company’s pipeline development strategy going forward, we are not comfortable to determine a specific price target. (1) clinical; (2) commercial; (3) partnership; (4) financial; and (5) intellectual property. Tocagen, Inc. September 12, 2019 H.C. WAINWRIGHT & CO." (9/12/2019)
Has Tocagen been receiving favorable news coverage?
News coverage about TOCA stock has been trending negative on Friday, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Tocagen earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Tocagen.
Who are some of Tocagen's key competitors?
Some companies that are related to Tocagen include Alpine Immune Sciences (ALPN), Inflarx (IFRX), Cumberland Pharmaceuticals (CPIX), Novan (NOVN), Aclaris Therapeutics (ACRS), Merrimack Pharmaceuticals (MACK), Eyenovia (EYEN), Lipocine (LPCN), Catalyst Biosciences (CBIO), VBI Vaccines (VBIV), NewLink Genetics (NLNK), Catabasis Pharmaceuticals (CATB), Elite Pharmaceuticals (ELTP), Aridis Pharmaceuticals (ARDS) and Infinity Pharmaceuticals (INFI).
What other stocks do shareholders of Tocagen own?
Who are Tocagen's key executives?
Tocagen's management team includes the folowing people:
- Mr. Martin J. Duvall, CEO & Director (Age 57)
- Mr. Thomas E. Darcy, Co-Founder & Director (Age 68)
- Dr. Douglas J. Jolly, Co-Founder and Exec. VP of Research & Pharmaceutical Devel. (Age 71)
- Mr. Mark G. Foletta C.P.A., CPA, Exec. VP & CFO (Age 58)
- Dr. Harry E. Gruber, Founder, Adviser & Director (Age 66)
When did Tocagen IPO?
(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel served as the underwriters for the IPO.
Who are Tocagen's major shareholders?
Tocagen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.00%), Vanguard Group Inc. (4.47%), Price T Rowe Associates Inc. MD (2.10%), JPMorgan Chase & Co. (2.00%), Northern Trust Corp (0.97%) and Acadian Asset Management LLC (0.39%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Institutional Ownership Trends for Tocagen.
Which institutional investors are selling Tocagen stock?
TOCA stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Morgan Stanley, D. E. Shaw & Co. Inc., Requisite Capital Management LLC, Jacobs Levy Equity Management Inc., TD Asset Management Inc. and Northern Trust Corp. View Insider Buying and Selling for Tocagen.
Which institutional investors are buying Tocagen stock?
TOCA stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, LPL Financial LLC, Acadian Asset Management LLC, JPMorgan Chase & Co., Wells Fargo & Company MN, IPG Investment Advisors LLC, A.R.T. Advisors LLC and Bank of New York Mellon Corp. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Insider Buying and Selling for Tocagen.
How do I buy shares of Tocagen?
Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Tocagen's stock price today?
One share of TOCA stock can currently be purchased for approximately $0.8103.
How big of a company is Tocagen?
Tocagen has a market capitalization of $19.36 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.
What is Tocagen's official website?
How can I contact Tocagen?
Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]
MarketBeat Community Rating for Tocagen (NASDAQ TOCA)
MarketBeat's community ratings are surveys of what our community members think about Tocagen and other stocks. Vote "Outperform" if you believe TOCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TOCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
